Welcome to our dedicated page for Structure Therapeutics ADR SEC filings (Ticker: GPCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Structure Therapeutics Inc. (NASDAQ: GPCR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Structure Therapeutics is incorporated in the Cayman Islands and its American Depositary Shares, each representing three ordinary shares, are registered and listed on the Nasdaq Global Market under the symbol GPCR. The company files reports and current updates with the U.S. Securities and Exchange Commission in connection with its operations and capital markets activities.
Investors reviewing GPCR SEC filings will find current reports on Form 8-K that cover topics such as quarterly financial results, corporate updates, and outcomes of the annual general meeting of shareholders. For example, the company has furnished press releases announcing second and third quarter financial results and business updates via Form 8-K, and has reported shareholder voting results on director elections, auditor ratification, and advisory votes on executive compensation and say-on-frequency matters.
Structure Therapeutics also utilizes an automatic shelf registration statement on Form S-3 to conduct public offerings of American Depositary Shares and pre-funded warrants. Related prospectus supplements and offering documents are filed with the SEC and referenced in the company’s press releases. These filings provide details on the terms of upsized underwritten public offerings, gross proceeds, and the involvement of joint book-running managers and co-managers.
Through this filings page, users can monitor how Structure Therapeutics reports its financial condition, shareholder actions, and significant corporate events in its SEC submissions. Stock Titan enhances access to these documents with tools to quickly locate relevant 8-Ks and registration-related materials and to follow the company’s ongoing reporting history as a Nasdaq-listed clinical-stage biopharmaceutical company focused on oral small molecule GPCR-targeted therapies.
Structure Therapeutics Inc received an amended Schedule 13G filing showing that FMR LLC and Abigail P. Johnson beneficially own 31,112,634 shares of its common stock, representing 15.0% of the class as of December 31, 2025.
FMR LLC has sole voting and dispositive power over these shares, while Abigail P. Johnson has sole dispositive power. The filers certify that the securities were acquired and are held on a passive basis, not to change or influence control of Structure Therapeutics.
FMR LLC, a 10% owner of Structure Therapeutics Inc. (GPCR), reported several sales of American Depositary Shares on January 15, 2026 through affiliated F-Prime funds. The trades, coded as open-market sales, included transactions such as 465 ADS at $82.10, 330 ADS at $83.35, 552 ADS at $84.22 and 20 ADS at $85.04 for F-Prime Capital Partners Life Sciences Advisors Fund VI LP, and larger blocks like 5,477 ADS at $82.10, 3,880 ADS at $83.35, 6,498 ADS at $84.22 and 230 ADS at $85.04 for F-Prime Capital Partners Life Sciences Fund VI LP.
After these trades, affiliated persons and entities whose holdings are reported by FMR LLC still held 4,546,674 ADS, while the two F-Prime funds held 5,005 ADS and 58,864 ADS, respectively. Each ADS represents three ordinary shares of Structure Therapeutics. The filing notes these positions are reported indirectly and includes a disclaimer that the reporting parties are not admitting beneficial ownership of the securities.
Structure Therapeutics Inc. (GPCR) reported a larger quarterly loss as it advanced multiple clinical programs and strengthened its balance sheet. For the three months ended September 30, 2025, net loss was $65,712 with a basic and diluted loss per share of $0.37, compared with a net loss of $33,977 and $0.20 per share a year ago. Operating expenses rose to $73,787, driven by research and development of $58,989 and general and administrative of $14,798. Interest and other income was $8,183.
The company ended the quarter with $799.0 million in cash, cash equivalents and short‑term investments and estimates this will fund projected operations through at least 2027. In September, it sold 3,040,000 ADSs via its ATM program for gross proceeds of approximately $58.5 million and net proceeds of approximately $55.8 million, leaving about $191.5 million capacity. Development highlights include Phase 2b ACCESS studies of aleniglipron (GLP‑1R agonist) with topline data expected by year‑end 2025, advancement of oral amylin receptor agonists (ACCG‑2671 and ACCG‑3535), completion of a Phase 1 study for LTSE‑2578 (LPA1R antagonist), and an asset sale to Exelixis with $10.0 million in initial payments (with $5.2 million received).
Structure Therapeutics Inc. furnished a current report describing a new press release that provides a corporate update and the company’s financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference for those detailed results.
The report clarifies that this information, including Exhibit 99.1, is furnished rather than filed under securities laws, which affects how it is treated for liability and incorporation into other regulatory documents.
Structure Therapeutics insider transaction: Reporting person Ashley Hall, identified as Chief Development Officer and a director, had 6,021 ordinary shares withheld to satisfy income tax obligations related to the vesting of restricted share units on 09/18/2025. The shares were recorded at a price of $7.7433 per share and reduced Hall's beneficial ownership to 112,317 ordinary shares. The filing notes that the issuer's ordinary shares may be represented by ADSs, with each ADS equal to three ordinary shares. This appears to be a routine tax-withholding disposition following equity vesting rather than an open-market sale.
Coll Crespo Blas, Chief Medical Officer of Structure Therapeutics Inc. (GPCR), reported a change in beneficial ownership for ordinary shares on 09/18/2025. The filing shows 8,106 ordinary shares were disposed (D) at a reported price of $7.7433 per share. After the transaction the reporting person beneficially owned 216,807 ordinary shares. The filing explains the 8,106 shares represent shares withheld by the issuer to satisfy income tax obligations related to the vesting of a restricted share unit award. The form notes that the issuer’s ordinary shares may be represented by ADSs, with each ADS equal to three ordinary shares.
Ma Yingli, Chief Technology Officer and director of Structure Therapeutics Inc. (GPCR), reported a Form 4 showing a transaction on 07/01/2025. The filing discloses a disposition of 4,470 ordinary shares at a price of $6.8366 per share, leaving 118,704 ordinary shares beneficially owned following the transaction.
The Form 4 notes these shares were withheld by the issuer to satisfy income tax obligations related to the vesting of a restricted share unit award. The report was executed by an attorney-in-fact, Jun Yoon, and is part of routine insider reporting under Section 16.
Structure Therapeutics Inc. (GPCR) reporting person Lin Xichen, who serves as Chief Scientific Officer and a director, disclosed a transaction on 07/01/2025 affecting her beneficial ownership. The filing shows 12,846 ordinary shares were disposed of through withholding to satisfy income tax obligations tied to the vesting of a restricted share unit award; the per‑share price reported for that disposition was $6.8366.
After the withholding transaction, Lin Xichen beneficially owns 204,327 ordinary shares, held directly. The filing notes that the company’s ordinary shares may be represented by ADSs, with each ADS equal to three ordinary shares. The form is a routine Section 16 report itemizing an insider tax‑related share withholding.
Structure Therapeutics Inc. received a Schedule 13G disclosing positions held by a group of affiliated Biotechnology Value Fund entities and Mark N. Lampert. Collectively the Reporting Persons beneficially own 9,611,751 Ordinary Shares, representing approximately 5.6% of the 172,793,818 shares outstanding (including ADSs) based on the issuer's July 31, 2025 share count. Individual holdings include BVF with 4,986,351 shares (about 2.9%), BVF2 with 3,902,022 shares (about 2.3%) and a Trading Fund OS with 530,763 shares (about 0.3%). The filing states these holdings were not acquired to change or influence control of the issuer.
Janus Henderson Group plc filed Amendment No. 3 to a Schedule 13G reporting ownership in Structure Therapeutics Inc. The filing lists 4,573,006 American Depositary Shares, representing 8.0% of the class, with shared voting and dispositive power. A subsidiary disclosure shows JHIUS may be deemed beneficial owner of 4,449,167 shares (7.7%) with shared voting and dispositive power. The report cites the event date 06/30/2025 and is signed on 08/14/2025 by Kristin Mariani. The filer certifies the position is held in the ordinary course and not to influence control. A power of attorney executed on 12/09/2022 is attached.